Diagnosis and treatment of the cardiovascular consequences of Fabry disease

• Published in: QJM : An International Journal of Medicine Vol. 112; no. 1; pp. 3 - 9
• Main Authors: Baig, S, Vijapurapu, R, Alharbi, F, Nordin, S, Kozor, R, Moon, J, Bembi, B, Geberhiwot, T, Steeds, R P
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.01.2019
• ISSN: 1460-2725; 1460-2393
• DOI: 10.1093/qjmed/hcy120

Abstract Fabry disease (FD) has been a diagnostic challenge since it was first recognized in 1898, with patients traditionally suffering from considerable delay before a diagnosis is made. Cardiac involvement is the current leading cause of death in FD. A combination of improved enzyme assays, availability of genetic profiling, together with more organized clinical services for rare diseases, has led to a rapid growth in the prevalence of FD. The earlier and more frequent diagnosis of asymptomatic individuals before development of the phenotype has focussed attention on early detection of organ involvement and closer monitoring of disease progression. The high cost of enzyme replacement therapy at a time of constraint within many health economies, moreover, has challenged clinicians to target treatment effectively. This article provides an outline of FD for the general physician and summarizes the aetiology and pathology of FD, the cardiovascular consequences thereof, modalities used in diagnosis and then discusses current indications for treatment, including pharmacotherapy and device implantation.